Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
Qi Fei, Fang Liu, Ling Gao
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 115

Showing 1-25 of 115 citing articles:

Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
Khaled Ezzedine, Elena Peeva, Yuji Yamaguchi, et al.
Journal of the American Academy of Dermatology (2022) Vol. 88, Iss. 2, pp. 395-403
Closed Access | Times Cited: 74
FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology
Ayesha Sheikh, Warisha Rafique, Rabia Owais, et al.
Annals of Medicine and Surgery (2022) Vol. 81
Open Access | Times Cited: 40
Vitiligo: A Review of Aetiology, Pathogenesis, Treatment, and Psychosocial Impact
Khadeejeh Al-Smadi, Mohammad Imran, Vânia Rodrigues Leite‐Silva, et al.
Cosmetics (2023) Vol. 10, Iss. 3, pp. 84-84
Open Access | Times Cited: 24
Tofacitinib combined with melanocyte protector α-MSH to treat vitiligo through dextran based hydrogel microneedles
Jingyao Liang, Yihui Yu, Changxing Li, et al.
Carbohydrate Polymers (2023) Vol. 305, pp. 120549-120549
Closed Access | Times Cited: 23
Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients
Yael Renert‐Yuval, Khaled Ezzedine, Pearl E. Grimes, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 4, pp. 453-453
Closed Access | Times Cited: 12
Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study
Thierry Passeron, Khaled Ezzedine, Iltefat Hamzavi, et al.
EClinicalMedicine (2024) Vol. 73, pp. 102655-102655
Open Access | Times Cited: 10
Application of Baricitinib in Dermatology
Jingya Zhang, Fei Qi, Jie Dong, et al.
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 1935-1941
Open Access | Times Cited: 30
Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro
Jie Dong, Xuan Huang, Li-Ping Ma, et al.
Dose-Response (2022) Vol. 20, Iss. 2
Open Access | Times Cited: 30
Combining network pharmacology, molecular docking, molecular dynamics simulation, and experimental verification to examine the efficacy and immunoregulation mechanism of FHB granules on vitiligo
Xiaolong Li, Fengze Miao, Rujuan Xin, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Etiopathogenesis and Emerging Methods for Treatment of Vitiligo
Tomasz Iwanowski, Karol Kołkowski, Roman Nowicki, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9749-9749
Open Access | Times Cited: 20
Pathogenic Th2 Cytokine Profile Skewing by IFN-γ-Responding Vitiligo Fibroblasts via CCL2/CCL8
Rong Jin, Miaoni Zhou, Fuquan Lin, et al.
Cells (2023) Vol. 12, Iss. 2, pp. 217-217
Open Access | Times Cited: 19
Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo
Emma Guttman‐Yassky, Ester Del Duca, Joel Corrêa da Rosa, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 153, Iss. 1, pp. 161-172.e8
Open Access | Times Cited: 19
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review
Aishwarya Muddebihal, Ananta Khurana, Kabir Sardana
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 4, pp. 279-295
Closed Access | Times Cited: 17
Vitiligo: Pathogenesis and New and Emerging Treatments
Javier Pérez-Bootello, Ruth Cova‐Martín, Jorge Naharro‐Rodríguez, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17306-17306
Open Access | Times Cited: 17
Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease
Margaret Y. Huang, April W. Armstrong
Indian Journal of Dermatology Venereology and Leprology (2023) Vol. 90, pp. 30-40
Open Access | Times Cited: 16
Tertiary Lymphoid Tissues Are Microenvironments with Intensive Interactions between Immune Cells and Proinflammatory Parenchymal Cells in Aged Kidneys
Takahisa Yoshikawa, Akiko Oguchi, Naoya Toriu, et al.
Journal of the American Society of Nephrology (2023) Vol. 34, Iss. 10, pp. 1687-1708
Open Access | Times Cited: 15
A combined spectroscopic and quantum chemical approach to study the molecular interaction between anti-inflammatory drug Hydrocortisone and amino acid l-Phenylalanine
Jyotshna Saikia, Th. Gomti Devi, T. Karlo
Journal of Molecular Structure (2023) Vol. 1286, pp. 135546-135546
Closed Access | Times Cited: 13
Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: A case report
Seyyon Satkunanathan, Mina Boshra, Janis Chang, et al.
SAGE Open Medical Case Reports (2024) Vol. 12
Open Access | Times Cited: 4
Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications
Marcelina Kądziela, Magdalena Kutwin, Paulina Karp, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4919-4919
Open Access | Times Cited: 4
Pathogenesis and regenerative therapy in vitiligo and alopecia areata: focus on hair follicle
Yuan Zhou, Yu-Xuan Zhang, Yuyun Xiong, et al.
Frontiers in Medicine (2025) Vol. 11
Open Access
Tofacitinib in focus: Fascinating voyage from conventional formulations to novel delivery systems
Priti Yadav, Sarika Wairkar
International Journal of Pharmaceutics (2025), pp. 125253-125253
Closed Access
Dietary Interventions, Supplements, and Plant-Derived Compounds for Adjunct Vitiligo Management: A Review of the Literature
Michael J. Diaz, Jasmine Tran, D W Rose, et al.
Nutrients (2025) Vol. 17, Iss. 2, pp. 357-357
Open Access
The small molecule ML233 is a direct inhibitor of tyrosinase function
Romain Menard, Aissette Baanannou, Caroline Halluin, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Serum untargeted metabolomics combined with mouse models reveals potential mechanisms of ChengShu QingChu decoction for the treatment of vitiligo
Xiangran Liu, Abudureyimu Alimujiang, Wenjing Wei, et al.
Journal of Chromatography B (2025) Vol. 1256, pp. 124538-124538
Closed Access
Emerging Therapeutic Innovations for Vitiligo Treatment
Weiran Li, Penghao Dong, Guanhua Zhang, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 191-191
Open Access
Page 1 - Next Page

Scroll to top